Clinic
Children's Hospital
Children's Hospital was paid $242.96M by Medicaid between Jan 2018 and Dec 2024, across 566 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 24% of everything it billed.
33Billing provider infoCHILDREN'S HOSPITAL
WASHINGTON, DC 20010
WASHINGTON, DC 20010
33aNPI1912939703assigned 07/06/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$242.96M
24GClaims2,196,636
24DCodes billed566
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in District of Columbia
Rank by total paid#1 of 22
Median peer was paid$2.28M
This provider vs. median107×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 341,643 | $34.23M | |
| 2019 | 379,753 | $31.65M | |
| 2020 | 271,684 | $18.28M | |
| 2021 | 371,515 | $32.86M | |
| 2022 | 323,052 | $41.74M | |
| 2023 | 252,281 | $38.23M | |
| 2024incomplete | 256,708 | $45.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 24% | 264,410 | 222,193 | $58.07M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 155,024 | 141,958 | $41.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 61,743 | 56,961 | $16.19M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.5% | 35,329 | 31,917 | $8.39M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 34,135 | 32,647 | $6.54M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.7% | 2,399 | 2,251 | $6.47M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 8,234 | 6,761 | $6.02M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.1% | 15,238 | 13,364 | $5.03M |
| G0378 | Hospital observation service, per hour | 2.0% | 19,758 | 11,677 | $4.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 12,475 | 11,874 | $4.34M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 14,134 | 12,540 | $3.49M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 17,601 | 16,491 | $3.39M |
554 more codes
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.4% | 17,238 | $3.39M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.4% | 5,535 | $3.38M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 14,184 | $2.77M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,205 | $2.76M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 1,276 | $2.65M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,103 | $2.35M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 10,116 | $2.10M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,176 | $1.87M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 932 | $1.82M |
| 92550 | <1% | 8,419 | $1.76M | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 8,746 | $1.76M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,355 | $1.62M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 11,324 | $1.51M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,206 | $1.49M |
| 94644 | <1% | 9,360 | $1.30M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,855 | $1.29M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,903 | $1.26M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,002 | $1.22M |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,448 | $1.18M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,956 | $1.16M |
| 54161 | <1% | 416 | $1.11M | |
| 42830 | <1% | 347 | $1.03M | |
| 36430 | <1% | 1,677 | $1.03M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,918 | $998K |
| 0225U | <1% | 4,268 | $964K | |
| 94010 | <1% | 7,343 | $939K | |
| 76770 | <1% | 3,148 | $845K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31,496 | $840K |
| 96112 | <1% | 848 | $816K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,308 | $774K |
| 95819 | <1% | 2,330 | $770K | |
| 12011 | <1% | 1,779 | $716K | |
| 93325 | <1% | 7,955 | $699K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 47,883 | $696K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,522 | $687K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,501 | $679K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,080 | $663K |
| 96127 | <1% | 13,257 | $651K | |
| 12001 | <1% | 1,510 | $625K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,068 | $585K |
| 96040 | <1% | 3,607 | $570K | |
| 92523 | <1% | 2,042 | $547K | |
| 95782 | <1% | 461 | $534K | |
| 80053 | Comprehensive metabolic panel | <1% | 39,097 | $527K |
| 95951 | <1% | 559 | $493K | |
| 99381 | <1% | 2,291 | $484K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,225 | $477K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,595 | $438K |
| 95816 | <1% | 1,037 | $431K | |
| 92579 | <1% | 5,703 | $408K | |
| 49452 | <1% | 715 | $398K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 308 | $391K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,266 | $383K |
| 95715 | <1% | 492 | $376K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 110 | $375K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,598 | $353K |
| 97161 | <1% | 1,462 | $338K | |
| 90651 | <1% | 1,100 | $335K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,004 | $334K |
| 16020 | <1% | 1,164 | $332K | |
| 90837 | Psychotherapy session, about an hour | <1% | 1,106 | $326K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,044 | $321K |
| 76536 | <1% | 1,583 | $313K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,757 | $286K |
| 92587 | <1% | 4,991 | $282K | |
| 83655 | <1% | 17,566 | $275K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12,016 | $266K |
| 93976 | <1% | 1,703 | $263K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 31,542 | $258K |
| 94060 | <1% | 1,915 | $240K | |
| 10060 | <1% | 554 | $238K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 201 | $224K |
| 95700 | <1% | 1,299 | $224K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 47,923 | $223K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 680 | $219K |
| 86922 | <1% | 2,486 | $214K | |
| 97802 | <1% | 1,262 | $211K | |
| 80061 | Lipid panel | <1% | 21,762 | $197K |
| 29075 | <1% | 500 | $195K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 756 | $192K |
| 96415 | <1% | 292 | $189K | |
| 92567 | <1% | 4,739 | $188K | |
| 76882 | <1% | 1,043 | $178K | |
| 93320 | <1% | 5,649 | $173K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,945 | $168K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 20,618 | $165K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14,623 | $165K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,009 | $165K |
| 96138 | <1% | 357 | $160K | |
| 29125 | <1% | 532 | $157K | |
| 92557 | <1% | 1,928 | $149K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 576 | $143K |
| 12051 | <1% | 320 | $141K | |
| 96156 | <1% | 592 | $138K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,552 | $137K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 738 | $136K |
| 87899 | <1% | 19,206 | $134K | |
| 86592 | <1% | 17,385 | $133K | |
| 87799 | <1% | 3,567 | $130K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,953 | $124K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,118 | $124K |
| 99383 | <1% | 629 | $121K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 398 | $121K |
| 76775 | <1% | 576 | $120K | |
| 86703 | <1% | 21,878 | $119K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 113 | $117K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 67 | $110K |
| 36415 | Collection of venous blood by venipuncture | <1% | 44,338 | $108K |
| 73590 | <1% | 3,999 | $104K | |
| 85018 | <1% | 19,794 | $103K | |
| 76825 | <1% | 1,239 | $102K | |
| 96130 | <1% | 151 | $96K | |
| 92555 | <1% | 3,686 | $94K | |
| 92552 | <1% | 2,305 | $93K | |
| 96160 | <1% | 1,935 | $93K | |
| 74018 | <1% | 2,905 | $92K | |
| 96139 | <1% | 258 | $90K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 702 | $89K |
| 97803 | <1% | 601 | $85K | |
| 0002A | <1% | 1,621 | $85K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,250 | $84K |
| J3490 | Unclassified drugs | <1% | 79,787 | $83K |
| 87497 | <1% | 2,558 | $82K | |
| 95712 | <1% | 190 | $82K | |
| 69210 | <1% | 1,040 | $79K | |
| 0001A | <1% | 1,629 | $76K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 334 | $76K |
| 87040 | <1% | 3,172 | $74K | |
| 82728 | <1% | 7,616 | $72K | |
| 72170 | <1% | 2,027 | $72K | |
| 96450 | <1% | 141 | $71K | |
| 76870 | <1% | 648 | $70K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,791 | $70K |
| 94645 | <1% | 1,897 | $67K | |
| 73630 | <1% | 4,746 | $64K | |
| 86480 | <1% | 2,542 | $61K | |
| 72081 | <1% | 1,610 | $61K | |
| 84439 | <1% | 6,368 | $57K | |
| 85007 | <1% | 12,771 | $56K | |
| 80197 | <1% | 3,318 | $54K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,129 | $52K |
| 73610 | <1% | 5,427 | $52K | |
| 72082 | <1% | 923 | $52K | |
| 92582 | <1% | 1,677 | $52K | |
| 70486 | <1% | 335 | $50K | |
| 73140 | <1% | 3,437 | $49K | |
| 82784 | <1% | 6,235 | $49K | |
| 83735 | <1% | 13,459 | $47K | |
| 64642 | <1% | 77 | $47K | |
| 76000 | <1% | 1,603 | $47K | |
| 77072 | <1% | 1,257 | $46K | |
| 93304 | <1% | 85 | $44K | |
| 85027 | <1% | 13,335 | $44K | |
| 92586 | <1% | 182 | $43K | |
| 73130 | <1% | 4,304 | $42K | |
| 83020 | <1% | 4,269 | $42K | |
| 73090 | <1% | 4,334 | $42K | |
| 80069 | <1% | 2,949 | $42K | |
| 76827 | <1% | 1,221 | $42K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,149 | $41K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 106 | $41K |
| 81001 | <1% | 19,857 | $41K | |
| 93225 | <1% | 1,368 | $41K | |
| 86850 | <1% | 4,951 | $40K | |
| 83970 | <1% | 1,378 | $40K | |
| 87536 | <1% | 1,154 | $40K | |
| 73100 | <1% | 1,660 | $38K | |
| 92553 | <1% | 563 | $38K | |
| 99384 | <1% | 205 | $38K | |
| 82664 | <1% | 1,043 | $37K | |
| 96367 | <1% | 824 | $37K | |
| 99382 | <1% | 167 | $36K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 842 | $34K |
| 81479 | Unlisted molecular pathology procedure | <1% | 570 | $34K |
| 92626 | <1% | 282 | $34K | |
| 87070 | <1% | 4,356 | $34K | |
| 73552 | <1% | 1,506 | $33K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,624 | $32K |
| 73080 | <1% | 2,591 | $32K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 7,402 | $32K |
| 74021 | <1% | 3,189 | $32K | |
| 0072A | <1% | 393 | $32K | |
| 0071A | <1% | 420 | $31K | |
| 73560 | <1% | 925 | $31K | |
| 92593 | <1% | 388 | $30K | |
| 86359 | <1% | 2,019 | $30K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 586 | $30K |
| 86900 | <1% | 5,019 | $29K | |
| 69200 | <1% | 331 | $29K | |
| 86945 | <1% | 1,772 | $28K | |
| 86140 | <1% | 7,226 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,232 | $28K |
| 73562 | <1% | 2,603 | $27K | |
| 11900 | <1% | 66 | $27K | |
| 96131 | <1% | 150 | $27K | |
| 86360 | <1% | 1,991 | $27K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 52 | $27K |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 3,197 | $26K |
| 84100 | <1% | 12,827 | $26K | |
| 84460 | <1% | 9,761 | $25K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 41 | $25K |
| 95012 | <1% | 566 | $25K | |
| 93226 | <1% | 1,366 | $25K | |
| 92585 | <1% | 78 | $25K | |
| 85045 | <1% | 10,662 | $25K | |
| 90686 | <1% | 621 | $24K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,772 | $23K |
| 87507 | <1% | 86 | $23K | |
| 97750 | <1% | 339 | $23K | |
| 73564 | <1% | 1,056 | $23K | |
| D1120 | Dental cleaning, child | <1% | 502 | $23K |
| 90620 | <1% | 395 | $22K | |
| 76885 | <1% | 95 | $22K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 22,142 | $22K |
| 83615 | <1% | 4,602 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 659 | $21K |
| 86834 | <1% | 199 | $21K | |
| 31575 | <1% | 184 | $21K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,982 | $20K |
| 82652 | <1% | 656 | $20K | |
| 92551 | <1% | 1,908 | $19K | |
| 82330 | <1% | 2,773 | $19K | |
| 87486 | <1% | 659 | $19K | |
| 86835 | <1% | 199 | $19K | |
| 88300 | <1% | 2,418 | $18K | |
| 83001 | <1% | 1,482 | $18K | |
| D0120 | Dental checkup, returning patient | <1% | 543 | $18K |
| 82947 | <1% | 3,648 | $18K | |
| D1206 | Topical application of fluoride varnish | <1% | 643 | $18K |
| 36592 | <1% | 354 | $18K | |
| 83498 | <1% | 1,251 | $18K | |
| 85610 | <1% | 4,679 | $18K | |
| 96409 | <1% | 861 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,902 | $17K |
| 82785 | <1% | 1,699 | $17K | |
| 85014 | <1% | 4,890 | $17K | |
| 86003 | <1% | 2,067 | $17K | |
| 83525 | <1% | 1,081 | $16K | |
| 82610 | <1% | 1,473 | $16K | |
| 87631 | <1% | 421 | $16K | |
| 80076 | <1% | 2,145 | $16K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 2,292 | $16K |
| 83516 | <1% | 1,865 | $16K | |
| 86901 | <1% | 5,011 | $16K | |
| 92060 | <1% | 706 | $16K | |
| 92592 | <1% | 175 | $15K | |
| 85651 | <1% | 6,702 | $15K | |
| 82570 | <1% | 3,544 | $15K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,087 | $15K |
| 92588 | <1% | 243 | $15K | |
| 82607 | <1% | 1,379 | $15K | |
| 86902 | <1% | 1,182 | $15K | |
| 84403 | <1% | 1,592 | $14K | |
| 87077 | <1% | 5,600 | $14K | |
| 81002 | <1% | 15,467 | $14K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 566 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,065 | $14K |
| 90670 | <1% | 85 | $14K | |
| 81025 | <1% | 16,874 | $13K | |
| 93308 | <1% | 26 | $13K | |
| 73110 | <1% | 1,124 | $13K | |
| 97165 | <1% | 58 | $13K | |
| 84436 | <1% | 1,586 | $13K | |
| 94664 | <1% | 6,142 | $13K | |
| 73030 | <1% | 1,210 | $13K | |
| 70360 | <1% | 615 | $12K | |
| 83880 | <1% | 873 | $12K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 4,240 | $12K |
| 95117 | <1% | 291 | $12K | |
| 87205 | <1% | 12,037 | $12K | |
| 83540 | <1% | 3,645 | $12K | |
| 82465 | <1% | 2,745 | $12K | |
| 93321 | <1% | 448 | $11K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,185 | $11K |
| 80050 | General health panel | <1% | 750 | $11K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,982 | $11K |
| 83002 | <1% | 1,419 | $11K | |
| 99070 | <1% | 1,047 | $11K | |
| 97162 | <1% | 66 | $11K | |
| 83550 | <1% | 3,191 | $10K | |
| 51728 | <1% | 28 | $10K | |
| 92504 | <1% | 196 | $10K | |
| 29065 | <1% | 35 | $10K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,402 | $10K |
| 86828 | <1% | 207 | $10K | |
| 97763 | <1% | 143 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,081 | $10K |
| 73521 | <1% | 345 | $10K | |
| 70544 | <1% | 26 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,135 | $9K |
| 73070 | <1% | 470 | $9K | |
| 24640 | <1% | 14 | $9K | |
| 84702 | <1% | 1,355 | $8K | |
| 82248 | <1% | 3,316 | $8K | |
| 77080 | <1% | 96 | $8K | |
| 87101 | <1% | 923 | $8K | |
| 89050 | <1% | 831 | $8K | |
| 84450 | <1% | 3,505 | $8K | |
| 88185 | <1% | 122 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 266 | $8K |
| 73000 | <1% | 389 | $8K | |
| 87581 | <1% | 628 | $8K | |
| 86355 | <1% | 570 | $8K | |
| A0434 | Specialty care transport (sct) | <1% | 467 | $8K |
| 82150 | <1% | 1,966 | $8K | |
| 83605 | <1% | 2,479 | $7K | |
| 85730 | <1% | 4,078 | $7K | |
| 84402 | <1% | 914 | $7K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 6,689 | $7K |
| 99000 | <1% | 3,290 | $7K | |
| 97760 | <1% | 54 | $7K | |
| A0425 | Ground mileage, per statute mile | <1% | 3,935 | $7K |
| 82948 | <1% | 3,986 | $7K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 7,232 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,885 | $7K |
| 82977 | <1% | 2,314 | $7K | |
| 73060 | <1% | 709 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,455 | $6K |
| 87535 | <1% | 162 | $6K | |
| 86803 | <1% | 637 | $6K | |
| 84305 | <1% | 623 | $6K | |
| 92652 | <1% | 74 | $6K | |
| 82139 | <1% | 473 | $6K | |
| 31526 | <1% | 13 | $6K | |
| 87186 | <1% | 4,906 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,527 | $6K |
| J7642 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram | <1% | 336 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,475 | $5K |
| 12002 | <1% | 13 | $5K | |
| 73660 | <1% | 472 | $5K | |
| 87529 | <1% | 335 | $5K | |
| 93886 | <1% | 17 | $5K | |
| 86357 | <1% | 556 | $5K | |
| 83690 | <1% | 4,045 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,618 | $5K |
| 92610 | <1% | 12 | $5K | |
| 90619 | <1% | 22 | $5K | |
| 88304 | <1% | 468 | $5K | |
| 86364 | <1% | 926 | $5K | |
| 17250 | <1% | 13 | $5K | |
| 82525 | <1% | 288 | $5K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 8,020 | $5K |
| 82803 | <1% | 1,978 | $5K | |
| 51784 | <1% | 43 | $4K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 10,660 | $4K |
| 82247 | <1% | 1,253 | $4K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 920 | $4K |
| 84146 | <1% | 480 | $4K | |
| 87340 | <1% | 988 | $4K | |
| 84550 | <1% | 2,009 | $4K | |
| 11981 | <1% | 13 | $4K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 983 | $4K |
| 82550 | <1% | 1,694 | $4K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 435 | $4K |
| 83520 | <1% | 687 | $4K | |
| 92595 | <1% | 133 | $4K | |
| 82657 | <1% | 657 | $4K | |
| 86160 | <1% | 692 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,522 | $3K |
| 85660 | <1% | 1,145 | $3K | |
| 72156 | <1% | 13 | $3K | |
| 82670 | <1% | 355 | $3K | |
| 90715 | <1% | 579 | $3K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 37 | $3K |
| 84480 | <1% | 857 | $3K | |
| 82043 | <1% | 1,182 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 380 | $3K |
| 86706 | <1% | 697 | $3K | |
| 87088 | <1% | 5,473 | $3K | |
| 88184 | <1% | 111 | $3K | |
| 82565 | <1% | 795 | $3K | |
| 92133 | <1% | 124 | $3K | |
| 84630 | <1% | 336 | $3K | |
| 83789 | <1% | 545 | $3K | |
| 87045 | <1% | 248 | $3K | |
| 90685 | <1% | 99 | $2K | |
| 89051 | <1% | 926 | $2K | |
| 82627 | <1% | 236 | $2K | |
| 82747 | <1% | 323 | $2K | |
| C1769 | Guide wire | <1% | 900 | $2K |
| 0352U | <1% | 229 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 727 | $2K |
| 80329 | <1% | 93 | $2K | |
| 74240 | <1% | 14 | $2K | |
| 36591 | <1% | 89 | $2K | |
| 84155 | <1% | 954 | $2K | |
| 84478 | <1% | 1,453 | $2K | |
| 92650 | <1% | 44 | $2K | |
| 86038 | <1% | 402 | $2K | |
| 80047 | <1% | 129 | $2K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 21 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 895 | $2K |
| 84156 | <1% | 1,234 | $2K | |
| 90688 | <1% | 42 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 310 | $2K |
| 84134 | <1% | 200 | $2K | |
| 94729 | <1% | 65 | $2K | |
| 81229 | <1% | 19 | $2K | |
| 92556 | <1% | 123 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,839 | $1K |
| 73600 | <1% | 66 | $1K | |
| 80320 | <1% | 104 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,072 | $1K |
| 80164 | <1% | 63 | $1K | |
| 72100 | <1% | 95 | $1K | |
| 85379 | <1% | 186 | $1K | |
| 83993 | <1% | 126 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 522 | $1K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 101 | $1K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,254 | $1K |
| 84295 | <1% | 1,843 | $1K | |
| 82261 | <1% | 209 | $1K | |
| 86701 | <1% | 181 | $1K | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 26 | $1K |
| 86769 | <1% | 246 | $1K | |
| 74230 | <1% | 12 | $1K | |
| 82533 | <1% | 84 | $1K | |
| 92511 | <1% | 14 | $999.78 | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 14 | $996.35 |
| 94726 | <1% | 12 | $944.88 | |
| G9019 | Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) | <1% | 491 | $941.38 |
| 74019 | <1% | 143 | $937.54 | |
| 84484 | <1% | 656 | $912.46 | |
| 82726 | <1% | 292 | $897.73 | |
| 82552 | <1% | 178 | $888.48 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 609 | $841.41 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 3,354 | $841.31 |
| 85240 | <1% | 130 | $834.28 | |
| 82960 | <1% | 304 | $826.34 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,300 | $825.77 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 14,619 | $808.49 |
| 84446 | <1% | 203 | $805.56 | |
| 83721 | <1% | 55 | $788.22 | |
| 97164 | <1% | 16 | $780.54 | |
| 90656 | <1% | 89 | $742.72 | |
| D0140 | Limited oral evaluation - problem focused | <1% | 18 | $722.65 |
| 84255 | <1% | 141 | $706.36 | |
| 92604 | <1% | 25 | $680.09 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 67 | $635.04 |
| 84590 | <1% | 172 | $618.38 | |
| 81003 | <1% | 5,350 | $600.07 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 474 | $592.07 |
| 84520 | <1% | 605 | $588.93 | |
| 99292 | <1% | 183 | $572.95 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,295 | $562.14 |
| 86376 | <1% | 25 | $559.98 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 12 | $552.00 |
| 86702 | <1% | 181 | $537.28 | |
| 84132 | <1% | 1,937 | $516.54 | |
| 84300 | <1% | 418 | $506.09 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 56 | $505.09 |
| 73502 | <1% | 27 | $496.72 | |
| D0272 | Bitewings - two radiographic images | <1% | 16 | $495.80 |
| 87102 | <1% | 125 | $465.50 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 622 | $465.25 |
| 87181 | <1% | 119 | $432.13 | |
| 72070 | <1% | 13 | $413.86 | |
| 86808 | <1% | 12 | $411.93 | |
| 85520 | <1% | 15 | $399.96 | |
| 96376 | <1% | 738 | $396.71 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $393.50 |
| 82776 | <1% | 195 | $373.00 | |
| 82760 | <1% | 195 | $373.00 | |
| 90734 | <1% | 71 | $366.88 | |
| 85246 | <1% | 74 | $358.26 | |
| 82272 | <1% | 112 | $349.14 | |
| 86704 | <1% | 96 | $328.94 | |
| 86747 | <1% | 14 | $326.10 | |
| 87046 | <1% | 161 | $324.91 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 39 | $314.81 |
| 73120 | <1% | 28 | $304.78 | |
| 86008 | <1% | 78 | $304.76 | |
| 85384 | <1% | 192 | $302.41 | |
| 82379 | <1% | 61 | $297.72 | |
| 81005 | <1% | 318 | $271.38 | |
| 80183 | <1% | 12 | $248.94 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 118 | $243.09 |
| 92594 | <1% | 13 | $239.45 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 61 | $234.66 |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 687 | $234.40 |
| 86225 | <1% | 75 | $228.82 | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 13 | $210.44 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 155 | $210.04 |
| 81015 | <1% | 3,769 | $188.20 | |
| 82805 | <1% | 189 | $175.70 | |
| 82105 | <1% | 14 | $173.26 | |
| 82542 | <1% | 25 | $170.97 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 299 | $153.33 |
| 86665 | <1% | 16 | $141.33 | |
| 51797 | <1% | 28 | $90.81 | |
| 87808 | <1% | 684 | $90.23 | |
| 77075 | <1% | 12 | $87.08 | |
| 84481 | <1% | 15 | $77.78 | |
| 85245 | <1% | 27 | $69.94 | |
| 86308 | <1% | 51 | $68.03 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,160 | $65.89 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 29 | $65.62 |
| 86317 | <1% | 27 | $64.67 | |
| J0200 | Injection, alatrofloxacin mesylate, 100 mg | <1% | 545 | $37.62 |
| 86141 | <1% | 127 | $32.57 | |
| 92015 | Determination of refractive state | <1% | 2,611 | $30.00 |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 631 | $29.10 |
| 80143 | <1% | 143 | $27.15 | |
| 90713 | <1% | 45 | $22.00 | |
| 80179 | <1% | 127 | $15.95 | |
| 86756 | <1% | 12 | $14.51 | |
| 88720 | <1% | 28 | $14.00 | |
| 82077 | <1% | 169 | $13.91 | |
| 87147 | <1% | 13 | $12.66 | |
| 87177 | <1% | 13 | $12.01 | |
| 76010 | <1% | 189 | $10.00 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 65 | $9.28 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 354 | $3.53 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 65 | $1.44 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 26 | $1.08 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 61 | $0.27 |
| 0250 | 0% | 2,604 | $0.00 | |
| 96368 | 0% | 48 | $0.00 | |
| 0710 | 0% | 157 | $0.00 | |
| 90680 | 0% | 32 | $0.00 | |
| 90744 | 0% | 114 | $0.00 | |
| 29130 | 0% | 15 | $0.00 | |
| 0270 | 0% | 38 | $0.00 | |
| 0370 | 0% | 110 | $0.00 | |
| 72157 | 0% | 12 | $0.00 | |
| 90716 | 0% | 23 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 25 | $0.00 |
| V5264 | Ear mold/insert, not disposable, any type | 0% | 29 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 26 | $0.00 |
| 96168 | 0% | 15 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 15 | $0.00 |
| 90698 | 0% | 37 | $0.00 | |
| V5275 | Ear impression, each | 0% | 12 | $0.00 |
| 80358 | 0% | 13 | $0.00 | |
| 94200 | 0% | 12 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 620 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 143 | $0.00 |
| 84145 | 0% | 29 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 84 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 45 | $0.00 |
| 0272 | 0% | 83 | $0.00 | |
| 69209 | 0% | 40 | $0.00 | |
| 90710 | 0% | 37 | $0.00 | |
| 0451 | 0% | 809 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 39 | $0.00 |
| 82375 | 0% | 23 | $0.00 | |
| 71048 | 0% | 26 | $0.00 | |
| 93356 | 0% | 16 | $0.00 | |
| A6211 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | 0% | 13 | $0.00 |
| 96167 | 0% | 66 | $0.00 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 14 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 29 | $0.00 |
| 90707 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNELSON, PHILLICIA (EXECUTIVE DIRECTOR, PAYOR RELATIONS)
| Provider | Location | Paid |
|---|---|---|
| Children's Hospital | Washington, DC | $115.27M |
| Hospital for Sick Children | Washington, DC | $4.66M |
| Children's Hospital | Washington, DC | $2.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.